Clinical Trial Update: Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) [Phase 2]

View source ↗

Summary

A Phase II basket trial is evaluating Zanidatamab in combination with Tislelizumab for HER2-positive gastrointestinal tumors, including rectal cancer, gastric c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Rectal Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)
• Zanidatamab

Snippet

Sponsor: Tao Zhang | Conditions: Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING